Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Musculoskeletal Diseases 1Joint Diseases 1Arthritis, Rheumatoid 1Arthritis 1

Interventions

Cyclophosphamide 1498Cisplatin 1434Paclitaxel 1339Radiotherapy 1309Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 802Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 678Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 515Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × upadacitinib × Clear all
NCT01960855 2021-08-24

A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy

AbbVie

Phase 2 Completed
276 enrolled 14 charts

Arthritis, Arthritis, Rheumatoid, Joint Diseases, Musculoskeletal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡